Translational Research

• ESMO Advanced Course on Biomakers for Precision Medicine
• Pathologic diagnosis: Improving accuracy in Asia and Europe
• ESMO recommendations for detecting MSI and TRK fusion (using NGS?)
• Precision medicine in cellular therapies: How can we identify patients who would benefit most
• New biomarkers for checkpoint inhibitor therapy
• Basic concepts in overcoming adaptive immune resistance
• Clinical applications of circulating tumour DNA in advanced setting
• Implications of NGS and molecular testing beyond RAS, RAF and MSI
• Predictive biomarkers for the efficacy of IO: which biomarkers to use for daily use?
• Predictive biomarkers for the efficacy of IO: What’s in the pipeline
• Emerging management paradigms in syndromes of high penetrance susceptibility: TP53 as an exemplar case
• Radiomics to predict sensitivity to immunotherapeutics
• Tweaking DNA repair pathways to improve cancer immune surveillance
• Clonal evolution of metastatic disease
• Digital pathology: Emerging technologies in the field
• Molecular Analysis for Personalised Therapy Congress 2019
• Proffered Paper - Public policy - Invited Discussant 1629O_PR and 1630O
• Conclusions and perspectives
• MMR repair driven neoantigens
• Conclusions and perspectives
• Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
• Platelets from metastatic cancer patients have increased aggregation and activation
• Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
• FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
• Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response...

• « Previous
• 1
• 2
• ...
• 122
• Next »